Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - fotivda
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpfba0a8367a83300af2a00b0c6fd0b172
identifier: http://ema.europa.eu/identifier
/EU/1/17/1215/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fotivda 890 microgram hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-fba0a8367a83300af2a00b0c6fd0b172
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/17/1215/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fotivda
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
The active substance in Fotivda is tivozanib, which is a protein kinase inhibitor. Tivozanib reduces the supply of blood to the cancer, which slows down the growth and spread of cancer cells. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF). Blocking the action of VEGF prevents the formation of new blood vessels.
Fotivda is used to treat adults with advanced kidney cancer. It is used where other treatments such as interferon-alpha or interleukin-2 have either not yet been used or have not helped to stop your disease.
Do not take Fotivda:
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Fotivda:
if you have high blood pressure Fotivda can increase your blood pressure. Your doctor will monitor your blood pressure regularly and, if it is too high, may either give you a medicine to lower it, or reduce your dose of Fotivda. However, if your blood pressure remains too high, your doctor may decide to interrupt or to stop treatment with Fotivda. If you are already taking a medicine to treat high blood pressure, and your doctor reduces the dose of Fotivda or interrupts or stops treatment, you will be regularly checked for low blood pressure.
if you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
if you have had problems with blood clots
Treatment with Fotivda may raise the risk of developing a blood clot (thrombus) in your blood vessels that could break loose and be carried by the blood stream to block another blood vessel.
Tell your doctor if you have ever had one of the following: * a blood clot in your lungs (with cough, chest pain, sudden shortness of breath or coughing up blood) * blood clot in your legs or arms, eye, or brain (with pain or swelling in your hands or feet, reduced vision, or changes in your mental state) * a stroke, or signs and symptoms of a mini-stroke (transient ischaemic attack) * a heart attack * high blood pressure * diabetes * major surgery * multiple injuries such as broken bones and damage to internal organs * inability to move for a long period * heart failure which can cause shortness of breath or ankle swelling * inability to breathe, bluish colour on your skin, fingertips or lips, restlessness, anxiety, confusion, altered consciousness or sense of awareness, rapid, shallow breathing, a racing heart or excessive sweating.
if you suffer or have suffered from any of these symptoms or are treated for heart failure: * Shortness of breath (dyspnoea) when you exert yourself or when you lie down * Feeling weak and tired * Swelling (oedema) in your legs, ankles and feet * Reduced ability to exercise * Persistent cough or wheezing with white or pink blood-tinged phlegm Signs and symptoms of heart failure will be monitored whilst you are taking your medicine. If necessary, your doctor may reduce your dose of Fotivda, or interrupt or stop this treatment.
If you have or are treated for an abnormal rate and rhythm of the heartbeat (arrhythmia) Your doctor will monitor the effect of Fotivda on your heart by recording the electrical activity of your heart (an electrocardiogram) or by measuring your blood calcium, magnesium and potassium levels during your treatment.
if you have problems with your liver
Your doctor will regularly monitor how well your liver is working before and during treatment with Fotivda (e.g. with blood tests), and if necessary may need to reduce how often you take Fotivda.
if you have problems with your thyroid gland or use medicines to treat thyroid disease Treatment with Fotivda may cause your thyroid gland to work less well than usual. Your doctor will regularly monitor how well your thyroid gland is working before and during treatment with Fotivda (e.g. with blood tests).
Talk to your doctor, pharmacist or nurse while taking Fotivda:
if you get shortness of breath or ankle swelling Tell your doctor right away as these may be symptoms of heart failure. Your doctor will monitor this, and depending on the severity may reduce your dose of Fotivda, or interrupt or stop treatment with Fotivda.
if you have had problems with bleeding Treatment with Fotivda may increase the risk of bleeding. If you get bleeding problems (with painful swollen stomach (abdomen), vomiting blood, coughing up blood, black stools, blood in your urine, headache or changes in your mental state), tell your doctor right away. Treatment with Fotivda may need to be temporarily stopped.
if laboratory tests show that there is protein in your urine
Your doctor will monitor this at the beginning and during your treatment. Depending on the results, your doctor may reduce your dose of Fotivda, or interrupt or stop this treatment.
if you suffer from a disease of the brain, called posterior reversible encephalopathy syndrome (PRES) Tell your doctor right away if you have symptoms such as headache, seizure (fit), lack of energy, confusion, blindness or other visual and neurologic disturbances such as weakness in an arm or a leg. If PRES is diagnosed, your doctor will stop treatment with Fotivda.
if the skin on the palms of your hands and the soles of your feet become dry, cracked, scaling, or peeling, or is stinging or tingling These may be symptoms of a condition called hand foot skin reaction. Your doctor will treat the condition and, depending on the severity, the doctor may reduce your dose of Fotivda, or interrupt or stop this treatment.
if you have symptoms of gastrointestinal perforation or fistula formation (developing a hole in the stomach or intestine or abnormal passages forming between parts of the intestine) such as severe stomach pain, chills, fever, nausea, vomiting or painful bowel obstruction, diarrhoea or rectal bleeding.
Your doctor will regularly monitor you for these symptoms during your treatment with Fotivda.
if you need to have an operation or another form of surgery Your doctor may recommend that you temporarily stop taking Fotivda if you have an operation or surgery, as it could affect wound healing.
Children and adolescents
Do not give Fotivda to children and adolescents under 18 years of age. This medicine has not been studied in children and adolescents.
Other medicines and Fotivda
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and other medicines you have bought without a prescription.
Fotivda may work less well when taken with some medicines. Tell your doctor if you are taking any of the following medicines; they may decide to change your medication:
Pregnancy, breast-feeding and fertility
Do not take Fotivda if you are pregnant. Tell your doctor who will discuss with you the risks of taking Fotivda to you and your child.
Both you and your partner must use effective contraception. If you or your partner are taking hormonal contraceptives (the pill, an implant or patch) you must use an additional barrier method throughout treatment and for another month after completing treatment.
Do not breast-feed during treatment with Fotivda, as it is not known whether the active ingredient in Fotivda passes into breast-milk. Talk to your doctor if you are already breast- feeding.
Talk to your doctor when planning a baby, as Fotivda may affect the fertility of men and women.
Driving and using machines Fotivda can have side effects that may affect your ability to drive or use machines. Avoid driving or using machines if you feel weak, tired, or dizzy. See also Section 4 Possible side effects .
Fotivda contains tartrazine (E102) The printing ink used on the Fotivda 890 microgram capsule contains tartrazine (E102), which may cause allergic reactions.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Recommended dose The recommended dose is one Fotivda 1340 microgram capsule, taken once daily for 21 days (3 weeks), followed by a 7-day (1-week) period when no capsules are taken.
This schedule is repeated in cycles of 4 weeks.
Your doctor will check you regularly, and you will normally continue to take Fotivda as long as it is working, and you do not suffer unacceptable side effects.
Reduced dose In case you experience severe side effects, your doctor may decide to interrupt Fotivda therapy and/or lower the dose to: One Fotivda 890 microgram capsule, taken once daily for 21 days (3 weeks), followed by a 7-day (1-week) period when no capsules are taken. This schedule is repeated in cycles of 4 weeks.
Liver problems If you have liver problems, your doctor may reduce how often you take your dose to every other day (i.e. one 1340 microgram capsule every other day).
Taking with food and drink Fotivda must be taken with a glass of water and can be taken either with or without food. Swallow the capsule whole. Do not chew, dissolve or open the capsule before swallowing.
If you take more Fotivda than you should Tell your doctor straightaway if you have taken more than your prescribed dose of 1 capsule per day.
21 days (three weeks)
One Fotivda capsule taken once daily 7 days (1 week)
No capsules are taken Taking too much Fotivda makes side effects more likely or to become more severe, especially high blood pressure. Get medical help straightaway if you experience confusion, changes in your mental state or headaches. These are all symptoms of high blood pressure.
If you forget to take Fotivda If you have missed taking a capsule, do not take a replacement capsule. Continue to take your next dose at the usual time.
Do not take a double dose to make up for a forgotten capsule.
If you vomit after taking Fotivda, do not take a replacement capsule. Continue to take your next dose at the usual time.
If you stop taking Fotivda
Do not stop taking this medicine unless your doctor tells you to. If you stop taking the capsules your condition may get worse.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
High blood pressure is the most serious and a very common side effect (see also in section 2 Warnings and Precautions ). Tell your doctor immediately if you think you have high blood pressure. Symptoms include severe headaches, blurred vision, shortness of breath, changes in your mental state, such as feeling anxious, confused or disorientated
Your doctor will check your blood pressure regularly during treatment with Fotivda. If you develop high blood pressure, your doctor may prescribe a medicine to treat your high blood pressure, lower your dose of Fotivda, or stop your treatment with Fotivda.
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (cannot be estimated from available data).
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.
Keep the bottle tightly closed in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Fotivda contains
Fotivda 890 microgram hard capsules
The active substance is tivozanib. Each capsule contains tivozanib hydrochloride monohydrate equivalent to 890 microgram of tivozanib. The other ingredients are:
Fotivda 1340 microgram hard capsules
The active substance is tivozanib. Each capsule contains tivozanib hydrochloride monohydrate equivalent to 1340 microgram of tivozanib. The other ingredients are:
What Fotivda looks like and contents of the pack Fotivda 890 microgram hard capsules have a dark blue opaque cap and bright yellow opaque body,
with TIVZ printed with yellow ink on the cap and LD on the body with dark blue ink.
Fotivda 1340 microgram hard capsules have a bright yellow opaque cap and bright yellow opaque
body, with TIVZ printed with dark blue ink on the cap and SD on the body with dark blue ink.
Fotivda 890 microgram and Fotivda 1340 microgram are available as packs of 21 capsules in HDPE-bottles with child-resistant closure.
Marketing Authorisation Holder Recordati Netherlands B.V. Beechavenue 54, 1119PW Schiphol-Rijk Netherlands
Manufacturer ALMAC PHARMA SERVICES (IRELAND) LIMITED Finnabair Industrial Estate Dundalk
Co. Louth
A91 P9KD
Ireland
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-fba0a8367a83300af2a00b0c6fd0b172
Resource Composition:
Generated Narrative: Composition composition-en-fba0a8367a83300af2a00b0c6fd0b172
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1215/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fotivda
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpfba0a8367a83300af2a00b0c6fd0b172
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpfba0a8367a83300af2a00b0c6fd0b172
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1215/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fotivda 890 microgram hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en